tocilizumab,obinutuzumab,glofitamab
jw pharma,roche
['lymsm', 'glofitamab']
glofitamab monotherapy (fixed duration) richter #17icml:
- 11 pts (all heavily pretreated, 100% refractory)
- orr 64% (46% cr), 80% of crs durable
- most crs gr1-2 (although 2 pts with gr3-4), only 1 gr3 icans
small cohort but prospect of durable crs in very promising. #lymsm 
Lymphoma doc & patient-reported outcomes researcher in #lymsm and #mmsm @CUHematology. Founder of https://t.co/kN6qeGFEox, @inTrainingDoc & @inHouseMag. 🏳️‍🌈